006 Therapeutic response guided dosing strategy to optimize long-term adalimumab treatment in patients with hidradenitis suppurativa: integrated results from the PIONEER phase 3 trials

MLA

Gulliver, W., et al. “006 Therapeutic Response Guided Dosing Strategy to Optimize Long-Term Adalimumab Treatment in Patients with Hidradenitis Suppurativa: Integrated Results from the PIONEER Phase 3 Trials.” Journal of Investigative Dermatology, vol. 136, no. 9, Number 9 Supplement 2, Sept. 2016, p. S161. EBSCOhost, https://doi.org/10.1016/j.jid.2016.06.023.

APA

Gulliver, W., Okun, M. M., Martorell, A., Geng, Z., Huang, X., Tang, Q., Williams, D. A., & Gu, Y. (2016). 006 Therapeutic response guided dosing strategy to optimize long-term adalimumab treatment in patients with hidradenitis suppurativa: integrated results from the PIONEER phase 3 trials. Journal of Investigative Dermatology, 136(9, Number 9 Supplement 2), S161. https://doi.org/10.1016/j.jid.2016.06.023

Chicago

Gulliver, W., M.M. Okun, A. Martorell, Z. Geng, X. Huang, Q. Tang, D.A. Williams, and Y. Gu. 2016. “006 Therapeutic Response Guided Dosing Strategy to Optimize Long-Term Adalimumab Treatment in Patients with Hidradenitis Suppurativa: Integrated Results from the PIONEER Phase 3 Trials.” Journal of Investigative Dermatology 136 (9, Number 9 Supplement 2): S161. doi:10.1016/j.jid.2016.06.023.